Tufts CSDD Impact Reports Single Issue

PLEASE NOTE: Orders are processed as quickly as possible during Tufts CSDD business hours of 9AM – 5PM. Orders placed outside of business hours or on weekends will be processed and delivered at the on the following business day.

2016
‚Äč

Global Regenerative Medicine Market Is Poised for Strong Growth
Jul/Aug, Vol. 18 No. 4

View summary          View Press Release         Purchase single issue

Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers
May/June, Vol. 18 No. 3

View summary          View Press Release         Purchase single issue

Promise of immuno-oncology therapies is boosting R&D funding, alliances
March/April, Vol. 18 No. 2

View summary          View Press Release         Purchase single issue

Amendments reduce number of patients, but at high cost, longer study times
January/February, Vol. 18 No. 1

View summary          View Press Release         Purchase single issue

2015

First-in-class drugs in competitive development races with later entrants
November/December, Vol. 17 No. 6

View summary          View Press Release         Purchase single issue

Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy
September/October, Vol. 17 No.5

View summary          View Press Release         Purchase single issue

Vaccine products in the R&D pipeline have more than tripled since 2005
July/August 2015, Vol. 17 No. 4

View summary          View Press Release         Purchase single issue

Personalized medicine gains traction but still faces multiple challenges
May/June 2015, Vol. 17 No. 3

View summary          View Press Release         Purchase single issue

Biosimilars entering the U.S. market are likely to face multiple challenges
March/April 2015, Vol. 17 No. 2

View summary          View Press Release         Purchase single issue

High turnover, protocol noncompliance plague the global site landscape
January/February 2015, Vol. 17 No. 1

View summary          View Press Release         Purchase single issue

2014

CNS drugs take longer to develop, have lower success rates, than other drugs
November/December 2014, Vol. 16 No. 6

View summary          View Press Release         Purchase single issue

Protocol design optimization starting to improve study performance
September/October 2014, Vol. 16 No. 5

View summary          View Press Release         Purchase single issue

Patients face new challenges accessing a growing number of orphan drugs
July/August 2014, Vol. 16 No. 4

View summary           View Press Release         Purchase single issue

Collaboration & risk-sharing programs experience longer development times
May/June 2014, Vol. 16 No. 3

View summary           View Press Release         Purchase single issue

Drug sponsors tread cautiously using social media to aid clinical research
March/April 2014, Vol. 16 No. 2

View summary           View Press Release         Purchase single issue

New Breakthrough Therapy Designation program aims to cut clinical trial time
January/February 2014, Vol. 16 No. 1

View summary           View Press Release         Purchase single issue

 

2013

Biotech products in Big Pharma clinical pipelines have grown dramatically
November/December 2013, Vol. 15 No. 6

View summary           View Press Release         Purchase single issue

Causes of clinical failures vary widely by therapeutic, phase of study
September/October 2013, Vol. 15 No. 5

View summary           View Press Release         Purchase single issue

Annual approvals for neglected diseases rose from 2.6 in 2000-08 to 5 in 2009-12
July/August 2013, Vol. 15 No. 4

View summary           View Press Release         Purchase single issue

Clinical success rates for new cancer drugs double while more enter testing
May/June 2013, Vol. 15 No. 3

View summary           View Press Release         Purchase single issue

Global site landscape remains highly fragmented with variable performance
March/April 2013, Vol. 15 No. 2

View summary           View Press Release         Purchase single issue

89% of trials meet enrollment, but timelines slip, half of sites under-enroll
January/February 2013, Vol. 15 No. 1

View summary           View Press Release         Purchase single issue

2012

One in five procedures generates extraneous clinical trials data
November/December 2012, Vol. 14 No. 6

View summary           View Press Release         Purchase single issue

Oncology drugs get faster approvals than non-oncology drugs in U.S.
September/October 2012, Vol. 14 No. 5

View summary           View Press Release         Purchase single issue

U.S. offers patients faster, greater access to cancer drugs than Europe
July/August 2012, Vol. 14 No. 4

View summary           View Press Release         Purchase single issue

User fee era in U.S. currently poses mixed regulatory burden for sponsors
May/June 2012, Vol. 14 No. 3

View summary           View Press Release         Purchase single issue

Pace of CNS drug development and FDA approvals lags other drug classes
March/April 2012, Vol. 14 No. 2

View summary           View Press Release         Purchase single issue

Study monitor workload high & varied with wide disparity by global region
January/February 2012, Vol. 14 No. 1

View summary           View Press Release         Purchase single issue

2011

New mAbs entering clinical study rose steadily from 1997 through 2010
November/December 2011, Vol. 13 No. 6

View summary           View Press Release         Purchase single issue

Nearly 60% of all protocols require amendments; one-third are avoidable
September/October 2011, Vol. 13 No. 5

View summary           View Press Release         Purchase single issue

Lack of clinically useful diagnostics hinder growth in personalized medicines
July/August 2011, Vol. 13 No. 4

View summary           View Press Release         Purchase single issue

Biopharmaceutical product approvals in the U.S. rose dramatically in 2000s 
May/June 2011, Vol. 13 No. 3

View summary           View Press Release         Purchase single issue

New or modified indications for existing drugs have steadily increased in U.S.
March/April 2011, Vol. 13 No. 2

View summary           View Press Release         Purchase single issue

U.S. healthcare stakeholders uncertain on benefits of risk evaluation strategy
January/February 2011, Vol. 13 No. 1

View summary            View Press Release            Purchase single issue

2010

Personalized medicine is playing a growing role in development pipelines
November/December 2010, Vol. 12 No. 6

View summary            View Press Release            Purchase single issue

Clinical approval success highest for smallest firms among the top 50
September/October 2010, Vol. 12 No. 5

View summary            View Press Release             Purchase single issue

Comparative effectiveness research impacts patient access to cancer drugs
July/August 2010, Vol. 12 No. 4

View summary            View Press Release             Purchase single issue

Rising protocol complexity, execution burden varies widely by phase and TA   
May/June 2010, Vol. 12 No. 3  
View summary            View Press Release             Purchase single issue

Rising demand is expanding scope and workload of regulatory affairs function
March/April 2010, Vol. 12 No. 2
View summary            View Press Release             Purchase single issue

U.S. orphan product designations more than doubled from 2000-02 to 2006-08
January/February 2010, Vol. 12 No. 1
View summary            View Press Release             Purchase single issue

2009
 

Drug approvals for neglected diseases increase along with more R&D funding
November/December 2009, Vol. 11 No. 6
View summary            View Press Release             Purchase single issue

Marketing exclusivity for first–in–class drugs has shortened to 2.5 years
September/October 2009, Vol. 11, No. 5
View summary            View Press Release             Purchase single issue

Large pharma success rate for drugs entering clinical trials in 1993–04: 16%
July/August 2009 Vol. 11, No. 4
View summary            View Press Release             Purchase single issue

Therapeutic peptides in clinical study in 2000–07 nearly doubled 1990s rate
May/June 2009, Vol. 11, No. 3
View summary            View Press Release             Purchase single issue

75% of U.S. health plans reimburse off–label uses of prescription drugs
March/April 2009, Vol. 11, No. 2
View summary            View Press Release             Purchase single issue

Current investigator landscape poses a growing challenge for sponsors
January/February 2009, Vol.11, No.1
View summary            View Press Release             Purchase single issue

2008


While total approvals decline, U.S. is preferred market for first launch
November/December 2008, Vol.10, No.6
View summary            View Press Release             Purchase single issue

Fast track designations more than doubled during the last five years
September/October 2008, Vol.10, No.5
View summary            View Press Release             Purchase single issue

Postmarketing studies are becoming the norm in U.S., Europe, and Japan
July/August 2008 Vol.10 No.4
View summary            View Press Release             Purchase single issue

Drug plans non–compliant with Medicare
May/June 2008, Vol.10, No.3
View summary            View Press Release             Purchase single issue

Number of mAbs entering clinical study nearly tripled in last decade
March/April 2008, Vol.10, No.2
View summary            View Press Release            Purchase single issue

Growing protocol design complexity stresses investigators, volunteers
January/February 2008, Vol.10, No.1
View summary            View Press Release             Purchase single issue

2007
 

Notable gender & racial disparities exist among clinical investigators
November/December 2007, Vol.9, No.6
View summary            View Press Release             Purchase single issue

Despite more cancer drugs in R&D, overall U.S. approval rate is 8%
September/October 2007, Vol.9, No.5 
View summary            View Press Release             Purchase single issue

Follow-on drugs and indications play key role for World Health Organization
July/August 2007, Vol. 9, No. 4
View summary            View Press Release             Purchase single issue

Challenges loom for postmarketing study commitments; benefits unclear
May/June 2007, Vol. 9, No. 3
View summary            View Press Release             Purchase single issue

Pediatric Study Costs Rose Substantially from 2000 as Complexity Grew
March/April 2007 Vol. 9, No. 2
View summary            View Press Release             Purchase single issue

EMEA meets performance goals, but lags U.S. FDA in drug approvals
January/February 2007 Vol.9 No.1
View summary            View Press Release             Purchase single issue

ABOUT RESEARCH COURSES & FORUMS LIBRARY & BIBLIOGRAPHY REPORTS SPONSORED RESEARCH NEWS